FWP - Forward Pharma A/S

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9700
+0.0600 (+6.59%)
At close: 1:50PM EDT
Stock chart is not supported by your current browser
Previous Close0.9100
Open0.9300
Bid0.9202 x 1000
Ask0.9900 x 900
Day's Range0.9600 - 0.9819
52 Week Range0.7100 - 2.3520
Volume540
Avg. Volume35,371
Market Cap46.111M
Beta (3Y Monthly)2.90
PE Ratio (TTM)N/A
EPS (TTM)-0.1280
Earnings DateNov 28, 2019 - Dec 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-09-12
1y Target Est37.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Forward Pharma A/S Announces Intention to Transfer its U.S. Public Listing to the Nasdaq Capital Market Stock Exchange

    Forward Pharma A/S (FWP) (the “Company”) today announced its intention to transfer its public listing of American Depositary Shares from the Nasdaq Global Select Market to the Nasdaq Capital Market. This follows the development in the Company’s American Depositary Shares (“ADSs” or “shares”) price after the Settlement and License Agreement with Biogen, and the significant return of capital to its shareholders in 2017. On June 21, 2019, the Company received a written notice from the Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the requirement for continued listing on the Nasdaq Global Select Market to maintain a minimum Market Value of Publicly Held Shares (“MVPHS”) of $5,000,000, as set forth in Nasdaq Listing Rule 5450(b)(1)(C) (the “MVPHS Notice”).

  • Introducing Forward Pharma (NASDAQ:FWP), The Stock That Collapsed 95%
    Simply Wall St.

    Introducing Forward Pharma (NASDAQ:FWP), The Stock That Collapsed 95%

    As an investor, mistakes are inevitable. But really bad investments should be rare. So take a moment to sympathize...

  • GlobeNewswire

    Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2018

    Forward Pharma A/S (FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2018. During the year ended December 31, 2017, we recognized as revenue the $1.25 billion nonrecurring non-refundable fee (“Non-refundable Fee”) that was received during February 2017 in connection with the Settlement and License Agreement (“License Agreement”) entered into with two wholly owned subsidiaries of Biogen, Inc. (collectively, “Biogen”).

  • GlobeNewswire

    Forward Pharma to Participate in the DKBIO2019 Life Science Investor Conference

    Forward Pharma A/S (FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the DKBIO2019 life science investor conference in New York, NY. Dr. Svendsen will present a corporate update on Thursday, April 11, 2019 at 1:00 PM ET and will be available for one-on-one meetings. Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications.

  • Reuters

    Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

    The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Biogen (BIIB.O) from future royalty payments to Forward. Biogen did not immediately respond to a request for comment. The companies had been locked in a dispute over patents for dimethyl fumarate, the key active ingredient in Tecfidera, the leading oral MS treatment.